Advertisement

Osteoporosis International

, Volume 17, Issue 10, pp 1514–1523 | Cite as

Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats

  • M. Saito
  • K. Fujii
  • Y. Mori
  • K. Marumo
Original Article

Abstract

Introduction

Diabetes is associated with an increased risk of fracture, although type 2 diabetes is often characterized by normal bone mineral density (BMD). Enzymatic and glycation-induced non-enzymatic cross-links play important roles in the expression of bone strength. The serum vitamin B6 concentration is lower in patients with diabetes than in healthy controls. The aim our study was to see if spontaneously diabetic WBN/Kob rats in the pre- and post-onset of diabetes would serve as a suitable model for studying the pathogenesis of the susceptibility to fracture in diabetes without the reduction of bone mineral density. Seventy male WBN/Kob rats were obtained at the ages of 1 to 18 months.

Methods

Seventy normal male Wistar rats were used as the non-diabetic, age-matched control. The contents of enzymatic cross-links (dihydroxylysinonorleucine, hydroxylysinonorleucine, lysinonorleucine, pyridinoline and deoxypyridinoline) and non-enzymatic cross-links (pentosidine) were determined in femoral bone. We also analyzed the serum concentration of vitamin B6 (pyridoxal and pyridoxamine), femoral BMD and a three-point bending test of the femur.

Results

A low level of serum vitamin B6 was associated with a decrease in enzymatic crosslinking in bone during the subclinical diabetes stage. After the onset of diabetes, there was a steady decrease in enzymatic cross-links and a steep increase in pentosidine. Furthermore, impaired bone mechanical properties in the WBN/Kob rats despite the lack of reduction in BMD coincided with impaired enzymatic cross-link formation and increases in glycation-induced pentosidine.

Conclusions

These results indicate that the alteration of enzymatic and non-enzymatic crosslinking in bone could be important for explaining the variation of fracture susceptibility in diabetes.

Keywords

Bone quality Collagen Cross-links Diabetes Pentosidine Vitamin B6 

Notes

Acknowledgements

The authors are grateful to Takaaki Tanaka (NHO National Utsunomiya Hospital, Tochigi, Japan) and Ms. Kazumi Hirakawa for experimental discussions and technical support.

References

  1. 1.
    Schwartz AV, Sellmeyer DE, Ensrud KE Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32–38PubMedCrossRefGoogle Scholar
  2. 2.
    NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRefGoogle Scholar
  3. 3.
    Viguet-Carrin S, Garnero P, Delmas PD (2005) The role of collagen in bone strength. Osteoporos Int, Dec 9; [Epub ahead of print]Google Scholar
  4. 4.
    Garnero P, Borel O, Gineyts E, Duboeuf F, Solberg H, Bouxsein ML, Christiansen C, Delmas PD (2006) Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38:300–309PubMedCrossRefGoogle Scholar
  5. 5.
    Wang X, Shen X, Li X, Agrawal CM (2002) Age-related changes in the collagen network and toughness of bone. Bone 31:1–7PubMedCrossRefGoogle Scholar
  6. 6.
    Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int, Mar 22; [Epub ahead of print]Google Scholar
  7. 7.
    Kuboki Y, Kudo A, Mizuno M, Kawamura M (1992) Time-dependent changes of collagen cross-links and their precursors in the culture of osteogenic cells. Calcif Tissue Int 50:473–480PubMedCrossRefGoogle Scholar
  8. 8.
    Uzawa K, Grzesik WJ, Nishiura T, Kuznetsov SA, Robey PG, Brenner DA, Yamauchi M (1999) Differential expression of human lysyl hydroxylase genes, lysyl hydroxylation, and cross-linking of type I collagen during osteoblastic differentiation in vitro. J Bone Miner Res 14:1272–1280PubMedCrossRefGoogle Scholar
  9. 9.
    Yamauchi M, Katz EP (1993) The post-translational chemistry and molecular packing of mineralizing tendon collagens. Connect Tissue Res 29:81–98PubMedCrossRefGoogle Scholar
  10. 10.
    Saito M, Soshi S, Fujii K (2003) Effect of hyper- and microgravity on collagen post-translational controls of MC3T3-E1 osteoblasts. J Bone Miner Res 18:1695–1705PubMedCrossRefGoogle Scholar
  11. 11.
    Saito M, Sohsi S, Tanaka T, Fujii K (2004) Intensity-related differences in collagen post-translational modification in MC3T3-E1 osteoblasts after exposure to low and high intensity pulsed ultrasound. Bone 35:644–655PubMedCrossRefGoogle Scholar
  12. 12.
    Saito M, Fujii K, Tanaka T, Soshi S (2004) Effect of low- and high-intensity pulsed ultrasound on collagen post-translational modifications in MC3T3-E1 osteoblasts. Calcif Tissue Int 75:384–385PubMedCrossRefGoogle Scholar
  13. 13.
    Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP (2001) Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28:195–201PubMedCrossRefGoogle Scholar
  14. 14.
    Paul RG, Bailey AJ (1996) Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol 28:1297–1310PubMedCrossRefGoogle Scholar
  15. 15.
    Oxlund H, Mosekilde L, Ortoft G (1996) Reduced concentration of collagen reducible crosslinks in human trabecular bone with respect to age and osteoporosis. Bone 19:479–484PubMedCrossRefGoogle Scholar
  16. 16.
    Paschalis EP, Shne E, Lyritis D, Skaeantavos G, Mandelsohn R, Boskey AL (2004) Bone fragility and collagen cross-links. J Bone Miner Res 19:2000–2004PubMedCrossRefGoogle Scholar
  17. 17.
    Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M (2001) Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 16:1821–1828PubMedCrossRefGoogle Scholar
  18. 18.
    Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N (1996) Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 11:931–937PubMedCrossRefGoogle Scholar
  19. 19.
    Saito M, Marumo K, Fujii K, Ishioka N (1997) Single column high - performance liquid chromatographic - fluorescence detection of immature, mature and senescent cross-links of collagen. Anal Biochem 253:26–32PubMedCrossRefGoogle Scholar
  20. 20.
    Bird TA, Levene CI (1982) Lysyl oxidase: evidence that pyridoxal phosphate is a co-factor. Biochem Biophys Res Commun 108:1172–1180PubMedCrossRefGoogle Scholar
  21. 21.
    Booth AA, Khalifah RG, Todd P, Hudson BG (1997) In vitro kinetics of formation of antigenic advanced glycation end products (AGEs): novel inhibitor of post-amadori glycation pathways. J Biol Chem 272:5430–5437PubMedCrossRefGoogle Scholar
  22. 22.
    Davis RE, Calder JS, Curnow DH (1976) Serum pyridoxal and folate concentrations in diabetes. Pathology 8:151–156PubMedCrossRefGoogle Scholar
  23. 23.
    Wilson RG, Davis RE (1977) Serum pyridoxal concentrations in children with diabetes mellitus. Pathology 9:95–99PubMedCrossRefGoogle Scholar
  24. 24.
    Okada M, Shibuya M, Yamamoto E, Murakami Y (1999) Effect of diabetes in vitamin B6 requirement in animals. Diabetes Obes Metab 1:221–225PubMedCrossRefGoogle Scholar
  25. 25.
    Mori Y, Yokoyama J, Nishimura M, Kurat H, Miura J, Ikeda Y (1990) Diabetic strain (WBN/kob) of rat characterized by endocrine-exocrine pancreatic impairment due to distinct fibrosis. Pancreas 5:452–459PubMedCrossRefGoogle Scholar
  26. 26.
    Mori Y, Yokoyama J, Nishimura M, Oka H, Mochio S, Ikeda Y (1992) Development of diabetic complications in new diabetic strain of rat (WBN/kob). Pancreas 7:569–577PubMedCrossRefGoogle Scholar
  27. 27.
    Eyre DR, Dickson IR, Van Ness K (1988) Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 252:495–500PubMedGoogle Scholar
  28. 28.
    Saito M (1999) Age-related changes in biochemical characteristics of collagen from human weight-bearing and non-weight-bearing bone. Tokyo Jikeikai Med J 114:327–337 (in Japanese)Google Scholar
  29. 29.
    Fujii K, Kuboki Y, Sasaki S (1976) Aging of human bone and articular cartilage collagen: changes in the reducible cross-links and their precursors. Gerontology 22:363–370PubMedCrossRefGoogle Scholar
  30. 30.
    Nanbara S, Tanaka K, Koide H, Tanaka T, Hayashi T (1990) Changes on levels of B6 vitamin and aminotransferase in liver of diabetic animals. Diab Res Clin Pract 9:109–114CrossRefGoogle Scholar
  31. 31.
    Havivi E, Bar On H, Reshef A, Stein P, Raz I (1991) Vitamins and trace metals status in non-insulin dependent diabetes mellitus. Int J Vitam Nutr Res 61:328–333PubMedGoogle Scholar
  32. 32.
    Fujii K, Kajiwara T, Kurosu H (1979) Effect of vitamin B6 deficiency on the crosslink formation of collagen. FEBS Lett 97:193–195PubMedCrossRefGoogle Scholar
  33. 33.
    Masse PG, Rimnac CM, Yamauchi M, Coburn SP, Rucker RB, Howell DS, Boskey AL (1996) Pyridoxine deficiency affects biomechanical properties of chick tibial bone. Bone 18:567–574PubMedCrossRefGoogle Scholar
  34. 34.
    Eyre DR (1981) Cross-links maturation of bone collagen. Dev Biochem 22:51–55Google Scholar
  35. 35.
    Robins SP, Ducan A (1983) Cross-linking of collagen. Location of pyridinoline in bovine articular cartilage at two sites of molecule. Biochem J 215:175–182PubMedGoogle Scholar
  36. 36.
    Schwartz AV (2003) Diabetes mellitus: Does it affect bone? Calcif Tissue Int 73:515–519PubMedCrossRefGoogle Scholar
  37. 37.
    Bayens JW (1991) Role of oxidative stress in development of complication of diabetes. Diabetes 40:676–683Google Scholar
  38. 38.
    Tsukahara H, Sekine K, Uchiyama M, Kawakami H, Hata I, Todoroki Y, Hiraoka M, Kaji M, Yorifuji T, Momoi T, Yoshihara K, Beppu M, Mayumi M (2003) Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr Res 54:419–424PubMedCrossRefGoogle Scholar
  39. 39.
    Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694PubMedGoogle Scholar
  40. 40.
    Reiser KM (1991) Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Exp Biol Med 196:17–29PubMedGoogle Scholar
  41. 41.
    Buffori F, Banchelli G, Dolara P, Igneti G, Pirisino R, Raimondi L, Ziche M (1985) Pyridoxamine as inhibitor of blood plasma benzyl amide oxidase and the other copper-containing amine oxidase. J Pharm Pharmacol 37:597–600Google Scholar
  42. 42.
    Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–2832PubMedCrossRefGoogle Scholar
  43. 43.
    Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555–11558PubMedCrossRefGoogle Scholar
  44. 44.
    Khatami M, Suldan Z, David I, Li W, Rockey JH (1988) Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. Life Sci 43:1725–1731PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2006

Authors and Affiliations

  1. 1.Department of Orthopaedic SurgeryJikei University School of MedicineTokyoJapan
  2. 2.Department of Diabetes and EndocrinologyJikei University School of MedicineTokyoJapan

Personalised recommendations